CannaPharmaRX, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CPMD research report →
Price Chart
About the company
CannaPharmaRX, Inc. is a Canadian enterprise actively involved in the cannabis sector. The company focuses on identifying, acquiring, and developing diverse projects for cultivating cannabis.
- CEO
- Constantine Nkafu
- IPO
- 1999
- Employees
- 26
- HQ
- Cremona, AB, CA
Get TickerSpark's AI analysis on CPMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.12M
- P/E
- -0.10
- PEG
- 0.00
- P/S
- 0.66
- P/B
- -0.04
- EV/EBITDA
- -1.99
- Div Yield
- 0.00%
- Gross Margin
- -88.82%
- Op Margin
- -170.13%
- Net Margin
- -666.19%
- ROE
- 39.79%
- ROIC
- 25.89%
Latest fiscal year · YoY change
- Revenue
- $1.36M+66.1%
- Gross Profit
- $-2,084,908+29.0%
- Op Income
- $-3,347,764
- Net Income
- $-11,131,448-12.4%
- EPS
- $-0.02-6.3%
- OCF Growth
- +53.5%
- FCF Growth
- +53.2%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.47
- RSI (14)
- 33
- Avg Volume
- 144.94K
No earnings-call transcripts are available for CPMD yet.
- Free Float
- 93.0%
- Shares Outstanding
- 678.50M
- Float Shares
- 631.33M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 25 | Tal Amir David | other | 0 |
| Mar 31, 25 | Tal Amir David | other | 0 |
| Mar 31, 25 | Tal Amir David | other | 0 |
| Mar 31, 25 | Tal Amir David | other | 0 |
| Mar 31, 25 | Zemel Elliot | other | 0 |
| Mar 31, 25 | Zemel Elliot | other | 0 |
| Mar 31, 25 | Zemel Elliot | other | 0 |
| Mar 31, 25 | Zemel Elliot | other | 0 |
| Aug 15, 23 | Panek Anthony Michael | other | 0 |
| Apr 20, 18 | SAMUELSON JAMES F | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CPMD coverage
Recent articles, reports, and earnings notes.
No research on CPMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CPMD report →CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026
accessnewswire.com · Jan 12
CannaPharmaRX Expands Cannabis Exports, Projects $1M+ Q3 Revenue
accessnewswire.com · Aug 19
CannapharmaRx Continues into New European Market with First Shipment Completed to Germany
accessnewswire.com · May 6
CannapharmaRx to Complete Additional Shipment in November
accesswire.com · Nov 5
CannaPharmaRx Receives Multiple Purchase Orders and Begins Delivery of Product
accesswire.com · Aug 15
Q1 2024 Financial Results
accesswire.com · Jun 28
CORRECTION FROM SOURCE: CannaPharmaRx to Host Investor Conference Call
https://www.accesswire.com · May 20
CannaPharmaRx to Host Investor Conference Call
https://www.accesswire.com · May 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.